首頁 > 市場調查報告書 > 製藥

神經疾病疼痛

市場調查報告書

商品編碼

1687496

神經病變疼痛市場規模、佔有率及成長分析（按產品類型、程序、技術、方式、購買類型和地區）－2025-2032 年產業預測

Neuropathic Pain Market Size, Share, and Growth Analysis, By Type, By Product Type, By Procedure, By Technology, By Modality, By Mode of Purchase, By Region - Industry Forecast 2025-2032

出版日期: 2025年03月20日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

神經病變疼痛市場規模預計在 2023 年達到 26.9 億美元，並從 2024 年的 28.3 億美元成長到 2032 年的 42.8 億美元，預測期內（2025-2032 年）的複合年成長率為 5.3%。

糖尿病等慢性疾病的盛行率不斷上升以及人口老化是神經病變疼痛盛行率不斷上升的主要因素。這一趨勢正在刺激旨在發現創新治療方法和藥物解決方案的重大研發活動，從而推動市場成長。此外，醫療保健專業人員和患者對有效管理神經病變疼痛的認知不斷提高，進一步推動了市場擴張。隨著製藥公司不斷推出新藥和治療方法以滿足未滿足的醫療需求，市場正在蓬勃發展，凸顯了創新和不斷發展的治療策略的動態模式。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 公司分部佔有率分析
- 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

Pfizer Inc.（USA）
Novartis AG（Switzerland）
Eli Lilly and Company（USA）
Johnson & Johnson（USA）
GlaxoSmithKline plc（UK）
Teva Pharmaceutical Industries Ltd.（Israel）
Astellas Pharma Inc.（Japan）
Abbott Laboratories（USA）
Medtronic plc（Ireland）
Boston Scientific Corporation（USA）
Biogen Inc.（USA）
Merck & Co., Inc.（USA）
Bristol Myers Squibb（USA）
AbbVie Inc.（USA）
Grunenthal GmbH（Germany）
AstraZeneca PLC（UK）
Daiichi Sankyo Company, Limited（Japan）

結論和建議

簡介目錄

Product Code: SQMIG35D2215

Neuropathic Pain Market size was valued at USD 2.69 billion in 2023 and is poised to grow from USD 2.83 billion in 2024 to USD 4.28 billion by 2032, growing at a CAGR of 5.3% during the forecast period (2025-2032).

The rising prevalence of chronic conditions like diabetes and an ageing population are key factors contributing to the increasing incidence of neuropathic pain. This trend is fostering significant research and development activities aimed at discovering innovative therapies and pharmaceutical solutions, which are propelling market growth. Moreover, heightened awareness among healthcare professionals and patients regarding effective neuropathic pain management further fuels this expansion. The market remains vibrant as pharmaceutical companies persistently launch new medications and treatment options to meet the unmet medical needs associated with neuropathic pain, highlighting a dynamic landscape of innovation and evolving therapeutic strategies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Neuropathic Pain market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Neuropathic Pain Market Segments Analysis

Global Neuropathic Pain Market is segmented by Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel and region. Based on Type, the market is segmented into Spinal Cord Stimulation (SCS) Devices, External Peripheral Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation (TENS) Devices, Focal Neuropathy, Automatic Neuropathy and Proximal Neuropathy. Based on Product Type, the market is segmented into Rechargeable and Non-Rechargeable. Based on Procedure, the market is segmented into Invasive and Non-Invasive. Based on Technology, the market is segmented into Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation and Respiratory Electrical Stimulation. Based on Modality, the market is segmented into Stationary and Portable. Based on Mode of Purchase, the market is segmented into Over-the-Counter Devices and Prescription-Based Devices. Based on Pain Type, the market is segmented into Peripheral Neuropathy, Entrapment Neuropathy, Phantom Limb Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, Foot Pain and Coccydynia. Based on Indication, the market is segmented into Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy and Others. Based on Diagnosis, the market is segmented into Imaging, Blood Tests and Physical Examination. Based on Treatment, the market is segmented into Medications and Multimodal Therapy. Based on End User, the market is segmented into Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Research Organization and Others. Based on Distribution Channel, the market is segmented into Direct Tender, Third Party Distributor and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Neuropathic Pain Market

The neuropathic pain market is significantly driven by the rising prevalence of chronic illnesses, including diabetes, various types of cancer, and neurological disorders, which has resulted in a greater incidence of neuropathic pain cases worldwide. As the global population ages, the associated risk factors for neuropathic pain are also increasing, further boosting market demand. Additionally, continuous advancements in research and pharmaceutical innovation are leading to the development of new medications and therapies specifically targeting neuropathic pain, thereby improving treatment options. Together, these factors are creating a robust environment for growth in the neuropathic pain market.

Restraints in the Neuropathic Pain Market

A significant constraint in the neuropathic pain market arises from the challenges linked to accurate diagnosis and the inherently subjective nature of pain assessment, which can hinder effective identification and measurement of neuropathic pain. This often results in underreporting or improper management of the condition. Additionally, the high costs associated with sophisticated treatment options and medications may further limit access to these therapies, particularly in regions with constrained healthcare budgets. These factors collectively hinder the growth of the market, affecting both patient outcomes and overall market dynamics in the management of neuropathic pain.

Market Trends of the Neuropathic Pain Market

The neuropathic pain market is witnessing a significant trend towards the development of innovative treatment modalities, driven by a robust focus on research and pharmaceutical advancements. This evolving landscape is catalyzed by the increasing recognition of neuropathic pain's complexities, prompting the exploration of tailored therapeutic solutions. Furthermore, the rise of telehealth and virtual healthcare platforms is transforming the diagnosis, monitoring, and management of neuropathic pain, making care more accessible and personalized. These advancements not only enhance patient engagement but also allow for real-time adjustments to treatment plans, ultimately improving outcomes and driving market growth in this dynamic sector.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Neuropathic Pain Market Size by Type & CAGR (2025-2032)

Market Overview
Spinal Cord Stimulation (SCS) Devices
External Peripheral Nerve Stimulation
Transcutaneous Electrical Nerve Stimulation (TENS) Devices
Focal Neuropathy
Automatic Neuropathy
Proximal Neuropathy

Global Neuropathic Pain Market Size by Product Type & CAGR (2025-2032)

Market Overview
Rechargeable
Non-Rechargeable

Global Neuropathic Pain Market Size by Procedure & CAGR (2025-2032)

Market Overview
Invasive
Non-Invasive

Global Neuropathic Pain Market Size by Technology & CAGR (2025-2032)

Market Overview
Transcutaneous Electrical Nerve Stimulation
Transcranial Magnetic Stimulation
Respiratory Electrical Stimulation

Global Neuropathic Pain Market Size by Modality & CAGR (2025-2032)

Market Overview
Stationary
Portable

Global Neuropathic Pain Market Size by Mode of Purchase & CAGR (2025-2032)

Market Overview
Over-the-Counter Devices
Prescription-Based Devices

Global Neuropathic Pain Market Size by Pain Type & CAGR (2025-2032)

Market Overview
Peripheral Neuropathy
Entrapment Neuropathy
Phantom Limb Neuropathy
Trigeminal Neuralgia
Post Herpetic Neuralgia (PHN)
Post Traumatic Neuropathy
Foot Pain
Coccydynia

Global Neuropathic Pain Market Size by Indication & CAGR (2025-2032)

Market Overview
Spinal Stenosis
Chemotherapy-Induced Peripheral Neuropathy
Diabetic Neuropathy
Others

Global Neuropathic Pain Market Size by Diagnosis & CAGR (2025-2032)

Market Overview
Imaging
Blood Tests
Physical Examination

Global Neuropathic Pain Market Size by Treatment & CAGR (2025-2032)

Market Overview
Medications
Multimodal Therapy

Global Neuropathic Pain Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals
Clinics
Home Healthcare
Ambulatory Surgical Centers
Research Organization
Others

Global Neuropathic Pain Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Direct Tender
Third Party Distributor
Others

Global Neuropathic Pain Market Size & CAGR (2025-2032)

North America (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
- US
- Canada
Europe (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boston Scientific Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grunenthal GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments